Literature DB >> 17118455

TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain.

David A Rhodes1, John Trowsdale.   

Abstract

TRIMs comprise a large protein family that include anti-retroviral restriction factors such as TRIM5alpha. Auto-antibodies to TRIM21 (Ro52) are a common serological feature of patients with Sjogren's syndrome and systemic lupus erythematosus (SLE). We show that, in addition to this autoantibody response, TRIM21 binds specifically to the Fc region of human IgG isotypes 1, 2 and 4, via a conformation dependent interaction. The minimal binding epitope was identified as the C-terminal B30.2 domain. The interaction was independent of N-linked glycosylation of the IgG CH2 domain. TRIM21 formed a trimer that competed with protein A for binding to IgG Fc. We conclude that TRIM21 binds to the consensus CH2/CH3 domain interface in the Fc region, overlapping the binding site of several other proteins, including Staphylococcus aureus protein A and Streptococcus spp. protein G. The data suggest that the normal function of TRIM21 involves regulation of IgG functions and that TRIM/B30.2 molecules may have broader and unsuspected roles in innate immunity, beyond that of retroviral restriction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118455     DOI: 10.1016/j.molimm.2006.10.013

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  39 in total

1.  Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts.

Authors:  Ryusuke Yoshimi; Tsung-Hsien Chang; Hongsheng Wang; Toru Atsumi; Herbert C Morse; Keiko Ozato
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

2.  Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies.

Authors:  Linn Strandberg; Aurelie Ambrosi; Alexander Espinosa; Lars Ottosson; Maija-Leena Eloranta; Wei Zhou; Ase Elfving; Edward Greenfield; Vijay K Kuchroo; Marie Wahren-Herlenius
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

3.  Severe Fever with Thrombocytopenia Syndrome Virus NSs Interacts with TRIM21 To Activate the p62-Keap1-Nrf2 Pathway.

Authors:  Younho Choi; Zhongyi Jiang; Woo-Jin Shin; Jae U Jung
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 4.  Structure and function of the SPRY/B30.2 domain proteins involved in innate immunity.

Authors:  Akshay A D'Cruz; Jeffrey J Babon; Raymond S Norton; Nicos A Nicola; Sandra E Nicholson
Journal:  Protein Sci       Date:  2013-01       Impact factor: 6.725

5.  Crystal structure of the TRIM25 B30.2 (PRYSPRY) domain: a key component of antiviral signalling.

Authors:  Akshay A D'Cruz; Nadia J Kershaw; Jessica J Chiang; May K Wang; Nicos A Nicola; Jeffrey J Babon; Michaela U Gack; Sandra E Nicholson
Journal:  Biochem J       Date:  2013-12-01       Impact factor: 3.857

6.  RIP2 promotes FcγR-mediated reactive oxygen species production.

Authors:  Michael G Shehat; Omar A Cardona; George F Aranjuez; Mollie W Jewett; Justine T Tigno-Aranjuez
Journal:  J Biol Chem       Date:  2019-05-21       Impact factor: 5.157

Review 7.  TRIM Proteins and Their Roles in Antiviral Host Defenses.

Authors:  Michiel van Gent; Konstantin M J Sparrer; Michaela U Gack
Journal:  Annu Rev Virol       Date:  2018-06-27       Impact factor: 10.431

Review 8.  Coordinated Neutralization and Immune Activation by the Cytosolic Antibody Receptor TRIM21.

Authors:  Adam J Fletcher; Leo C James
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

9.  Trim65: a cofactor for regulation of the microRNA pathway.

Authors:  Shitao Li; Lingyan Wang; Bishi Fu; Martin E Dorf
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

10.  Dynamic movements of Ro52 cytoplasmic bodies along microtubules.

Authors:  Makoto Tanaka; Kunikazu Tanji; Motoko Niida; Tetsu Kamitani
Journal:  Histochem Cell Biol       Date:  2009-12-16       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.